Our mission is to deliver best-in-class therapeutics to patients with debilitating eye diseases

See How

Pursuing Innovative Ocular Biotherapeutics

Ocugen, Inc. is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. The Company’s lead clinical candidate (OCU300) is currently in Phase 3 for treating ocular graft versus host disease (oGVHD) and is the first and only therapeutic with orphan drug designation for oGVHD, providing certain regulatory and economic benefits. The Company's second lead candidate for treating dry eye disease (OCU310) is also expected to enter pivotal clinical trials in 2018. Both OCU300 and OCU310 leverage Ocugen's patented OcuNanoE - Ocugen's ONE Platform™ technology to enhance the efficacy of topical ophthalmic therapeutics. Ocugen is also developing novel biologic therapies for retinitis pigmentosa (OCU100) and wet AMD (OCU200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (OCU400).
Sign up to receive email alerts with the latest news from Ocugen Subscribe